• In early June 2026, Revvity announced plans to divest its immunodiagnostics business in China, which accounted for about 6% of revenue, after reporting first-quarter results that included 6% pro forma organic growth and a 24% adjusted operating margin across Life Sciences, Diagnostics, and SaaS software.
• This move signals a refocus on higher-growth, higher-margin areas while shedding a business constrained by policy challenges and cash flow pressures in China.
• Next, we’ll examine how the planned China immunodiagnostics divestiture could reshape Revvity’s existing investment narrative and earnings outlook.

We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Revvity Investment Narrative Recap

To own Revvity, you need to believe in its ability to shift toward higher-margin life sciences, diagnostics, and software while managing policy and funding headwinds. The planned divestiture of the China immunodiagnostics unit looks directionally aligned with that thesis and may modestly ease near term growth and margin pressures, but it does not remove the biggest current risk, which is ongoing regulatory and reimbursement change in key healthcare markets, particularly China and other cost constrained regions.

Among recent announcements, the reaffirmed outlook around Q1 2026 results, including 6% pro forma organic growth and a 24% adjusted operating margin, is most relevant here. Against that backdrop, the planned exit from a business that accounted for about 6% of revenue will likely matter most for how investors think about the quality and mix of future earnings, rather than as a standalone driver of Revvity’s overall revenue trajectory in the near term.

Yet while the divestiture may ease some China exposure, investors should be aware that...

Revvity's narrative projects $3.2 billion revenue and $411.5 million earnings by 2029. This requires 3.7% yearly revenue growth and about a $172 million earnings increase from $239.1 million today.

Uncover how Revvity's forecasts yield a $113.64 fair value, a 16% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already assuming revenue of about US$3.3 billion and earnings near US$697 million by 2029, yet they see China policy risk and execution challenges around the divestiture as reasons the story could still disappoint compared with the more optimistic consensus.

Explore 2 other fair value estimates on Revvity - why the stock might be worth just $113.64!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Revvity research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Revvity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Revvity's overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 48 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.